Study on THIO and Cadonilimab for Resectable Hepatocellular Carcinoma Launched
A clinical trial is underway to evaluate the efficacy and safety of cadonilimab alone and in combination with ateganosine for treating resectable HCC.
Asset / Drug
Drug and asset intelligence for cadonilimab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.